Time to remission and kinetics of CLL blood indices during treatment with Ibr or Ibr + R. (A) Number of patients in CR at 12 and 24 months. (B) Bone marrow CLL disease levels, quantified by using flow cytometry, at baseline and after 12 and 24 months of treatment. (C) Trended mean ± SD ALC in patients treated with Ibr (blue line) or with Ibr + R (green line). (D) Trended mean ± SD β₂-microglobulin levels in patients treated with Ibr or with Ibr + R. (E) Trended mean ± SD hemoglobin levels in patients treated with Ibr or with Ibr + R. (F) Trended mean ± SD platelet counts in patients treated with Ibr or with Ibr + R. CR/CRI, CRs with incomplete count recovery.